AdAlta says Oribiotech customer deal validates its IRO manufacturing plan
AdAlta (ASX:1AD) says its automated IRO manufacturing strategy has gained commercial validation after Oribiotech secured a major long-term customer under a 10-year agreement worth up to US$120 million.
AdAlta Limited ASX:1AD said its planned automated manufacturing platform has received commercial validation for future cellular immunotherapies after partner Oribiotech secured a major long-term customer. Oribiotech signed a 10-year agreement worth up to US$120 million with an undisclosed customer.